CA3034328A1 - Immunogenic composition - Google Patents
Immunogenic composition Download PDFInfo
- Publication number
- CA3034328A1 CA3034328A1 CA3034328A CA3034328A CA3034328A1 CA 3034328 A1 CA3034328 A1 CA 3034328A1 CA 3034328 A CA3034328 A CA 3034328A CA 3034328 A CA3034328 A CA 3034328A CA 3034328 A1 CA3034328 A1 CA 3034328A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- influenza
- composition
- region
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614485.9A GB201614485D0 (en) | 2016-08-25 | 2016-08-25 | Immunogenic composition |
| GB1614485.9 | 2016-08-25 | ||
| PCT/GB2017/052510 WO2018037246A1 (en) | 2016-08-25 | 2017-08-25 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3034328A1 true CA3034328A1 (en) | 2018-03-01 |
Family
ID=57119951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3034328A Pending CA3034328A1 (en) | 2016-08-25 | 2017-08-25 | Immunogenic composition |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11123422B2 (https=) |
| EP (1) | EP3504235A1 (https=) |
| JP (2) | JP7203015B2 (https=) |
| CN (1) | CN109923125B (https=) |
| AU (3) | AU2017315238A1 (https=) |
| CA (1) | CA3034328A1 (https=) |
| GB (1) | GB201614485D0 (https=) |
| WO (1) | WO2018037246A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201614485D0 (en) * | 2016-08-25 | 2016-10-12 | Univ Oxford Innovation Ltd | Immunogenic composition |
| WO2020061443A2 (en) * | 2018-09-21 | 2020-03-26 | Board Of Regents Of The University Of Nebraska | Methods of making and using universal centralized influenza vaccine genes |
| GB2578163A (en) * | 2018-10-19 | 2020-04-22 | Univ Pretoria | Plant produced avian influenza antigens and their uses in diagnostic assays and devices |
| GB202204478D0 (en) * | 2022-03-29 | 2022-05-11 | Univ Oxford Innovation Ltd | Immunogenic compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| CA2035576A1 (en) | 1990-02-07 | 1991-08-08 | Alexander R. Neurath | Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1 |
| AU727602B2 (en) | 1995-09-01 | 2000-12-14 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| AU2003228267A1 (en) * | 2002-03-05 | 2003-09-22 | Board Of Regents, The University Of Texas System | Methods of enhancing immune induction involving mda-7 |
| AU2006236910B2 (en) * | 2005-04-11 | 2012-06-07 | Purdue Research Foundation | Vaccine against pandemic strains of influenza viruses |
| WO2007134327A2 (en) * | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| CN104140958A (zh) * | 2006-08-09 | 2014-11-12 | 米迪缪尼有限公司 | 流感血凝素和神经氨酸酶变体 |
| NZ590351A (en) | 2008-07-18 | 2012-11-30 | Medicago Inc | HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region |
| WO2011126370A1 (en) | 2010-04-09 | 2011-10-13 | Universiteit Utrecht Holding B.V. | Recombinant multimeric influenza proteins |
| CA2807664A1 (en) * | 2010-08-12 | 2012-02-16 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
| US8883171B2 (en) | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| CN104582714A (zh) * | 2012-05-23 | 2015-04-29 | 斯坦福大学托管董事会 | 流感疫苗构建体 |
| US8932598B2 (en) * | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| ES2803508T3 (es) | 2013-03-28 | 2021-01-27 | Medicago Inc | Producción de partículas similares al virus de la gripe en plantas |
| GB201614485D0 (en) * | 2016-08-25 | 2016-10-12 | Univ Oxford Innovation Ltd | Immunogenic composition |
-
2016
- 2016-08-25 GB GBGB1614485.9A patent/GB201614485D0/en not_active Ceased
-
2017
- 2017-08-25 US US16/326,749 patent/US11123422B2/en active Active
- 2017-08-25 EP EP17758932.2A patent/EP3504235A1/en active Pending
- 2017-08-25 AU AU2017315238A patent/AU2017315238A1/en not_active Abandoned
- 2017-08-25 JP JP2019511574A patent/JP7203015B2/ja active Active
- 2017-08-25 WO PCT/GB2017/052510 patent/WO2018037246A1/en not_active Ceased
- 2017-08-25 CN CN201780051719.XA patent/CN109923125B/zh active Active
- 2017-08-25 CA CA3034328A patent/CA3034328A1/en active Pending
-
2021
- 2021-08-27 US US17/458,712 patent/US12390518B2/en active Active
-
2022
- 2022-12-26 JP JP2022209044A patent/JP7762643B2/ja active Active
-
2024
- 2024-10-28 AU AU2024227680A patent/AU2024227680A1/en active Pending
-
2026
- 2026-01-05 AU AU2026200025A patent/AU2026200025A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018037246A4 (en) | 2018-04-19 |
| US20190201521A1 (en) | 2019-07-04 |
| AU2026200025A1 (en) | 2026-01-22 |
| JP2019534242A (ja) | 2019-11-28 |
| JP2023052092A (ja) | 2023-04-11 |
| US20220054625A1 (en) | 2022-02-24 |
| GB201614485D0 (en) | 2016-10-12 |
| AU2017315238A1 (en) | 2019-02-21 |
| CN109923125A (zh) | 2019-06-21 |
| WO2018037246A1 (en) | 2018-03-01 |
| US11123422B2 (en) | 2021-09-21 |
| EP3504235A1 (en) | 2019-07-03 |
| AU2024227680A1 (en) | 2024-11-21 |
| JP7762643B2 (ja) | 2025-10-30 |
| US12390518B2 (en) | 2025-08-19 |
| JP7203015B2 (ja) | 2023-01-12 |
| CN109923125B (zh) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12390518B2 (en) | Immunogenic composition | |
| US20230165952A1 (en) | Betacoronavirus prophylaxis and therapy | |
| JP7655849B2 (ja) | ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター | |
| US11389525B2 (en) | Polygene influenza vaccine | |
| CN105452270B (zh) | 流行性感冒病毒疫苗及其用途 | |
| US10729758B2 (en) | Broadly reactive mosaic peptide for influenza vaccine | |
| JP2023522154A (ja) | インフルエンザワクチン | |
| JP5730204B2 (ja) | インフルエンザm2由来の改変ペプチドワクチン | |
| CN118076646A (zh) | 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用 | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| US20260007734A1 (en) | Immunogenic compositions for the prevention of influenza a | |
| KR102959050B1 (ko) | 변형된 사스-코로나바이러스-2 ORF3a 폴리펩타이드 및 이의 용도 | |
| KR20260056047A (ko) | 변형된 사스-코로나바이러스-2 ORF3a 폴리펩타이드 및 이의 용도 | |
| WO2024235368A1 (es) | Composicion vacunal contra el virus de la peste porcina africana | |
| WO2026074282A1 (en) | Influenza vaccines | |
| CN117957017A (zh) | 包含重组重叠肽和天然蛋白质的疫苗制剂 | |
| HK40090677A (zh) | 流感疫苗 | |
| CN111065400A (zh) | 抗流感药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220526 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240808 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240808 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20241011 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250715 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250715 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250811 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250811 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260128 |